The splicing factor kinase SRPK1 is a therapeutic target for Peripheral Vascular Disease
Authors:
- Jason O AmarteyJAJason O Amartey
- Amira ZawiaAZAmira Zawia
- Maria Jc MachadoMMMaria Jc Machado
Preprint
Abstract
Introduction: In peripheral arterial disease (PAD) anti-angiogenic VEGF-A 165 b isoform overexpression in monocytes contributes to impaired collateralisation. Serine-arginine protein-kinase-1 (SRPK1) regulates VEGF splicing. To determine whether SRPK1 controlled monocytic VEGF, impairing collateralisation, we investigated SRPK1 inhibition and monocyte-specific knockout in mouse models of and in human monocytes from PAD. Methods: VEGF-A 165 b activity was measured by co-culture of PAD patients’ monocytes with endothelial cells with SRPK1 inhibition. Mice with impaired revascularisation due to soluble-frizzled-related-protein-5 knockout (Sfrp5 -/- ), monocyte-specific Wnt5a gain-of-function (LysM-Wnt5a GOF ), or obese mice on a high-fat high-sucrose (HF/HS) diet were subjected to femoral artery ligation and treated with SRPK1 inhibitor. We generated an SRPK1 conditional knockout and crossed it with monocyte-specific (LysM-Cre) driver line to specifically knockout SRPK1 in monocyte lineages. Blood flow was measured by Laser Speckle Imaging before, and for 28 days after surgery. Results: Monocytes from PAD patients significantly inhibited endothelial cell migration, which was reversed by an anti-VEGF-A 165 b antibody. Surprisingly, migration was stimulated by SRPK1 inhibition, switching splicing from VEGF-A 165 b to VEGF-A 165 a. In Sfrp5 -/- , LysM-Wnt5a GOF and HF/HS mouse models of PAD, blood flow was improved by SRPK1 inhibition. Impaired revascularisation in LysM-Wnt5a GOF mice was rescued in LysM-Wnt5a GOF :SRPK1 MoKO mice, which had a phenotypic shift towards M2 macrophages. Impaired blood flow recovery was also rescued in obese-SRPK1 MoKO mice. Conclusion: VEGF splicing in monocytes is regulated differently from VEGF splicing in epithelial or cancer cells suggesting that control of splicing is dependent on cell type and/or environment. SRPK1 inhibition enhances collateralisation in mice, and in human in vitro models of monocyte-dependent impaired angiogenesis. New and Noteworthy: A novel potential treatment for peripheral arterial disease (PAD) is described. Inhibition of SRPK1, or knockout in monocytes, induces angiogenesis by preventing splicing to anti-angiogenic VEGF (VEGF-A 165 b) in patients and animal models. In PAD, monocyte splicing control is different from other cell types and SRPK1 inhibition by drug like compounds can alter macrophage phenotype and reverse PAD in mice using a new cell specific SRPK1-LoxP mouse.Keywords
All Related Versions
- Published version: American Journal of Physiology-Heart and Circulatory Physiology.
This publication has 48 references indexed in Scilit:
- Protein-protein interaction inhibitor of SRPKs alters the splicing isoforms of VEGF and inhibits angiogenesisiScience, 2021
- Real-Time Ligand Binding of Fluorescent VEGF-A Isoforms that Discriminate between VEGFR2 and NRP1 in Living CellsCell Chemical Biology, 2018
- IL-4 Regulates Specific Arg-1+ Macrophage sFlt-1–Mediated Inhibition of AngiogenesisThe American Journal of Pathology, 2015
- Programmed Translational Readthrough Generates Antiangiogenic VEGF-AxCell, 2014
- Both Decreased and Increased SRPK1 Levels Promote Cancer by Interfering with PHLPP-Mediated Dephosphorylation of AktMolecular Cell, 2014
- Plasma SFRP5 levels are decreased in Chinese subjects with obesity and type 2 diabetes and negatively correlated with parameters of insulin resistanceDiabetes Research and Clinical Practice, 2013
- WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF SplicingCancer Cell, 2011
- Immune cells in adipose tissue: Key players in metabolic disordersDiabetes & Metabolism, 2011
- IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxiaImmunobiology, 2010
- A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2Cellular and Molecular Life Sciences, 2006